US OptionsDetailed Quotes

EDIT241220C2500

Watchlist

0.25
-0.01-3.85%

15min DelayClose Nov 22 16:00 ET

0.35High0.25Low

Editas Medicine Stock Discussion

Trytosaveabit

Oct 22 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...

Jaguar8

Oct 3 23:44

AH NEWS TODAY

$Editas Medicine (EDIT.US)$
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...

wompwomp1337

Sep 6 06:09

$Editas Medicine (EDIT.US)$ seems like Feng Zhang and his team are making leeway with the ultra selfish gene

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...

Jaguar8

May 10 05:01

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...

Jaguar8

Apr 22 15:32

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Moomoo AI

Mar 9 06:33

Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Moomoo AI

Mar 2 06:23

Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.

Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Moomoo AI

Feb 29 04:33

Increased forecast losses for Editas Medicine indicate potential issues, with revenues expected to grow slower than the market. The drastic downgrade to this year's forecasts raises caution towards the company's future performance.

Revenue Downgrade: Here's What Analysts Forecast For Editas Medicine, Inc. (NASDAQ:EDIT)

Moomoo AI

Feb 29 04:31

Editas Medicine's share price bounce is expected after a significant drop, but the underlying business needs to justify a higher price. The weak revenue result is concerning, and the falling share price is likened to 'trying to catch a falling knife'. The recent share price recovery is viewed skeptically.

Editas Medicine (NASDAQ:EDIT) Shareholders Are up 40% This Past Week, but Still in the Red Over the Last Three Years

No comment yet